insulin drugs glp 1 receptor agonist market GLP-1 Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Agonists Weight Loss Drugs
Description
Medicaid coverage for weight loss medications, including GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound), varies dramatically from state to sta...
Ozempic (semaglutide) is a medication used to manage type 2 diabetes
Who it's for
Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
